Search research articles
Contact Us
Filters
Showing results (31-40 of 84) with videos related to
Page
of 9
Sort By:
International Journal of Technology Assessment in Health Care
|
September 15, 2016
TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALS
Chris Henshall, Nicholas R Latimer, Lloyd Sansom, et al.
Pharmacoeconomics
|
April 1, 2024
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments
Jen-Yu Amy Chang, James B Chilcott, Nicholas R Latimer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 24, 2025
An Assessment of the Maturity of Cancer Survival Data Used in Economic Models for the National Institute for Health and Care Excellence's Single Technology Appraisals
Jiyeon Kang, John Cairns, Nicholas R Latimer, et al.
Pharmacoeconomics
|
October 30, 2017
A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis
Shijie Ren, Jonathan Minton, Sophie Whyte, et al.
Public Health Nutrition
|
August 5, 2021
Rationalisation of meat consumption in New Zealand adolescents
Kelly R Latimer, Meredith C Peddie, Tessa Scott, et al.
Statistical Methods in Medical Research
|
June 27, 2018
Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
N R Latimer, I R White, K R Abrams, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 19, 2016
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight
Anthony J Hatswell, Joshua Porter, Dawn Lee, et al.
Spine
|
July 1, 1981
Brain abscess as a complication of halo traction
D E Humbyrd, F R Latimer, J E Lonstein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 12, 2021
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making
Ting-An Tai, Nicholas R Latimer, Ágnes Benedict, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 23, 2022
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum
Antonia Morga, Nicholas R Latimer, Martin Scott, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 84) with videos related to
Sort By:
Page
of 9
International Journal of Technology Assessment in Health Care
|
September 15, 2016
TREATMENT SWITCHING IN CANCER TRIALS: ISSUES AND PROPOSALS
Chris Henshall, Nicholas R Latimer, Lloyd Sansom, et al.
Pharmacoeconomics
|
April 1, 2024
Challenges and Opportunities in Interdisciplinary Research and Real-World Data for Treatment Sequences in Health Technology Assessments
Jen-Yu Amy Chang, James B Chilcott, Nicholas R Latimer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
July 24, 2025
An Assessment of the Maturity of Cancer Survival Data Used in Economic Models for the National Institute for Health and Care Excellence's Single Technology Appraisals
Jiyeon Kang, John Cairns, Nicholas R Latimer, et al.
Pharmacoeconomics
|
October 30, 2017
A New Approach for Sampling Ordered Parameters in Probabilistic Sensitivity Analysis
Shijie Ren, Jonathan Minton, Sophie Whyte, et al.
Public Health Nutrition
|
August 5, 2021
Rationalisation of meat consumption in New Zealand adolescents
Kelly R Latimer, Meredith C Peddie, Tessa Scott, et al.
Statistical Methods in Medical Research
|
June 27, 2018
Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
N R Latimer, I R White, K R Abrams, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
December 19, 2016
The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight
Anthony J Hatswell, Joshua Porter, Dawn Lee, et al.
Spine
|
July 1, 1981
Brain abscess as a complication of halo traction
D E Humbyrd, F R Latimer, J E Lonstein, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
April 12, 2021
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making
Ting-An Tai, Nicholas R Latimer, Ágnes Benedict, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 23, 2022
Is Intention to Treat Still the Gold Standard or Should Health Technology Assessment Agencies Embrace a Broader Estimands Framework?: Insights and Perspectives From the National Institute for Health and Care Excellence and Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use E9 (R1) Addendum
Antonia Morga, Nicholas R Latimer, Martin Scott, et al.
Page
of 9